Physician profile
Deepika Garg
NPI 1679879373
$3,951.44
in general payments reported to CMS, 2019-2025
28 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $646 · 2021: $1,005 · 2022: $809 · 2023: $224 · 2024: $412 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $705.06 | 2019-2023 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $683.93 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.71 | 2020-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $311.09 | 2019-2023 | Segluromet, Steglatro |
| Tactile Systems Technology INC | $291.91 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Medtronic, INC. | $291.52 | 2024 | Closurefast, Venaseal |
| Jazz Pharmaceuticals INC. | $191.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $156.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $100.03 | 2021 | |
| Amarin Pharma, INC. | $96.89 | 2020-2021 | |
| Coopersurgical, INC. | $74.28 | 2019 | |
| Abbvie INC. | $72.51 | 2021 | |
| Exact Sciences Corporation | $64.74 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $63.90 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $60.26 | 2022-2023 | Sunosi |
| Glaxosmithkline, LLC. | $42.87 | 2019-2021 | |
| Lilly USA, LLC | $38.75 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $38.25 | 2020-2021 | |
| Allergan, INC. | $37.29 | 2019-2020 | |
| Abbott Laboratories | $29.70 | 2022 | |
| Koya Medical, INC. | $21.63 | 2025 | Koya Medical, Dayspring |
| Invivyd INC | $18.68 | 2025 | Pemgarda |
| Dexcom, INC. | $18.27 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $16.80 | 2023 | |
| Beone Medicines USA, INC. | $16.02 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $14.64 | 2019 | |
| Bausch Health US, LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.